Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Interest Income
Income earned on cash, deposits, and investments held by the company.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $1.44M fell 35.4% year over year, behind the -30.1% change in trailing-twelve-month interest income. Sequentially, it fell 12.8% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.
Context
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -35.4% toward the trailing-twelve-month pace of -30.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 7.87M USD
- Year-over-year change
- -27.0%
- 4-year CAGR
- +121.1%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.87M | -27.0% |
| FY2024 | 2024-12-31 | 10.78M | -14.1% |
| FY2023 | 2023-12-31 | 12.55M | +115.8% |
| FY2022 | 2022-12-31 | 5.82M | +1667.8% |
| FY2021 | 2021-12-31 | 329K | — |
Interest Income vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's LTM Mar 2026 interest income of $7.08M is the 5th highest of the 11 companies compared; the peer median is $4.34M.
- Its year-over-year change of -30.1% is the 4th highest of 11, against a peer median of -37.7%.
- Over three fiscal years its annual growth of +10.6% compares with a peer median of +50.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.27M | -47.9% | +57.6% | 20.4% | |
| LTM Mar 2026 | $8.9M | -24.3% | +82.0% | 12.9% | |
| LTM Mar 2026 | $7.8M | -35.9% | +15.5% | 27.6% | |
| LTM Mar 2026 | $7.16M | +42.0% | +80.4% | 10.1% | |
| LTM Mar 2026 | $7.08M | -30.1% | +10.6% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $5.84M | -32.1% | +2131.8% | — |
| LTM Mar 2026 | $2.84M | -27.6% | +11.1% | 1262.2% | |
| LTM Mar 2026 | $2.83M | -58.0% | +9.3% | 20.4% | |
| LTM Mar 2026 | $2.26M | -39.6% | -0.5% | 111.9% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $800K | -90.5% | +119.5% | — |
| LTM Mar 2026 | -$411.45M | -18576.2% | +44.2% | — | |
| Peer median (excluding NAUT) | $4.34M | -37.7% | +50.9% | 20.4% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Gross Profit | (2.84M) | (3.42M) | (5.71M) | (6.35M) | (6.47M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 26.51M | 36.46M | 47.25M | 50.48M | 41.11M |
| Selling, General & Admin | 21.15M | 23.75M | 28.9M | 31M | 25.73M |
| Operating Expenses | 47.66M | 60.2M | 70.45M | 75.12M | 60.37M |
| Depreciation & Amortization | 2.84M | 3.42M | 1.85M | 6.35M | 6.47M |
| EBITDA | (47.47M) | (54.51M) | (61.83M) | (64.43M) | (52.54M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.5M) | (63.62M) | (76.15M) | (81.48M) | (66.84M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 329K | 5.82M | 12.55M | 10.78M | 7.87M |
| Interest Expense | 0 | 5.82M | 0 | 0 | 0 |
| Other Income / Expenses | 183K | 5.69M | 12.48M | 10.7M | 7.84M |
| Income Before Tax | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| EPS (Diluted) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| Weighted Avg Shares | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
| Weighted Avg Shares (Diluted) | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.